Welcome to our dedicated page for Decoy Therapeutics SEC filings (Ticker: DCOY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoy Therapeutics Inc. filings document the company's public-company governance, capital structure, and corporate-status records following its name change from Salarius Pharmaceuticals, Inc. to Decoy Therapeutics Inc. The filing record includes Form 8-K reports on certificate and bylaw amendments, the DCOY trading symbol, Nasdaq Capital Market listing matters, and amendments affecting common stock.
Proxy and meeting disclosures cover shareholder voting matters, including approval of an equity incentive plan and authorization for a reverse stock split. Additional filings describe the completed 1-for-12 reverse stock split, related security-holder rights changes, Nasdaq minimum bid price compliance, governance procedures, operating and financial results, and other material-event reporting for the issuer.
Decoy Therapeutics Inc. reported that stockholders approved all matters presented at a virtual special meeting held on February 24, 2026. The meeting had a quorum with 2,696,758 common shares represented. Stockholders approved the 2026 Equity Incentive Plan, providing a new framework for equity-based compensation.
They also approved a reverse stock split of outstanding common stock at a ratio between 1-for-4 and 1-for-15, with the exact ratio to be set at the board’s discretion. An adjournment proposal was approved as well, but the meeting did not need to be adjourned because sufficient votes were obtained for the main proposals.
Decoy Therapeutics Inc. investor reports a 9.9% passive stake. CVI Investments, Inc. and Heights Capital Management, Inc. jointly report beneficial ownership of 708,565 shares of Decoy Therapeutics common stock, all issuable upon exercise of warrants.
Their ownership represents 9.9% of the common stock, based on 6,384,177 shares outstanding as of December 26, 2025, as cited from the company’s definitive proxy statement. The warrants are subject to a 9.99% beneficial ownership cap, limiting exercise if it would push total holdings above that level. The filers certify the securities were not acquired to change or influence control of the company.